A tumor sorting protocol that enables enrichment of pancreatic adenocarcinoma cells and facilitation of genetic analyses

Journal of Molecular Diagnostics

Volumn 11, Issue 4, 2009, Pages 290-297

  Boyd, Zachary S ^a   Raja, Rajiv ^a   Johnson, Stephanie ^a   Eberhard, David A ^a   Lackner, Mark R ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CARCINOMA CELL; CELL SELECTION; CHROMOSOME; CLINICAL ARTICLE; CONTROLLED STUDY; DNA FINGERPRINTING; FEMALE; FLOW CYTOMETRY; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; MUTATION; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; AGED; BASE SEQUENCE; CELL SEPARATION; DNA MUTATIONAL ANALYSIS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 69249148729     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2009.080124     Document Type: Article

References (31)

1. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK: Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004, 101:3-27
2. Bardeesy N, DePinho RA: Pancreatic cancer biology and genetics. Nat Rev 2002, 2:897-909
3. Baumgart M, Heinmoller E, Horstmann O, Becker H, Ghadimi BM: The genetic basis of sporadic pancreatic cancer. Cell Oncol 2005, 27:3-13
4. Klimstra DS, Longnecker DS: K-ras mutations in pancreatic ductal proliferative lesions. Am J Pathol 1994, 145:1547-1550
5. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997, 57:1731-1734
6. Coppola D, Lu L, Fruehauf JP, Kyshtoobayeva A, Karl RC, Nicosia SV, Yeatman TJ: Analysis of p53, p21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival. Am J Clin Pathol 1998, 110:16-23
7. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S: Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993, 142:1534-1543
8. Ebert MP, Fei G, Schandl L, Mawrin C, Dietzmann K, Herrera P, Friess H, Gress TM, Malfertheiner P: Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br J Cancer 2002, 86:257-262
9. Franko J, Krasinskas AM, Nikiforova MN, Zarnescu NO, Lee KK, Hughes SJ, Bartlett DL, Zeh Iii HJ, Moser AJ: Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. J Gastrointest Surg 2008, 12:1664-1672
10. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271:350-353
11. Nowak NJ, Gaile D, Conroy JM, McQuaid D, Cowell J, Carter R, Goggins MG, Hruban RH, Maitra A: Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet 2005, 161: 36-50
12. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B: Mutations of mitotic checkpoint genes in human cancers. Nature 1998, 392:300-303
13. Naderi A, Couch FJ: BRCA2 and pancreatic cancer. Int J Gastrointest Cancer 2002, 31:99-106
14. Moore PS, Beghelli S, Zamboni G, Scarpa A: Genetic abnormalities in pancreatic cancer. Mol Cancer 2003, 2:7
15. Seymour AB, Hruban RH, Redston M, Caldas C, Powell SM, Kinzler KW, Yeo CJ, Kern SE: Allelotype of pancreatic adenocarcinoma. Cancer Res 1994, 54:2761-2764
16. Shekouh AR, Thompson CC, Prime W, Campbell F, Hamlett J, Herrington CS, Lemoine NR, Crnogorac-Jurcevic T, Buechler MW, Friess H, Neoptolemos JP, Pennington SR, Costello E: Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 2003, 3:1988-2001
17. Bjorheim J, Minarik M, Gaudernack G, Ekstrom PO: Mutation detection in KRAS exon 1 by constant denaturant capillary electrophoresis in 96 parallel capillaries. Anal Biochem 2002, 304:200-205
18. Karhu R, Mahlamaki E, Kallioniemi A: Pancreatic adenocarcinoma - genetic portrait from chromosomes to microarrays. Genes Chromosom Cancer 2006, 45:721-730
19. Schubert EL, Hsu L, Cousens LA, Glogovac J, Self S, Reid BJ, Rabinovitch PS, Porter PL: Single nucleotide polymorphism array analysis of flow-sorted epithelial cells from frozen versus fixed tissues for whole genome analysis of allelic loss in breast cancer. Am J Pathol 2002, 160:73-79
20. Bartek J, Vojtesek B, Staskova Z, Bartkova J, Kerekes Z, Rejthar A, Kovarik J: A series of 14 new monoclonal antibodies to keratins: characterization and value in diagnostic histopathology. J Pathol 1991, 164:215-224
21. Huang J, Wei W, Zhang J, Liu G, Bignell GR, Stratton MR, Futreal PA, Wooster R, Jones KW, Shapero MH: Whole genome DNA copy number changes identified by high density oligonucleotide arrays. Hum Genom 2004, 1:287-299
22. Zhao X, Li C, Paez JG, Chin K, Janne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C, Gray JW, Sellers WR, Meyerson M: An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004, 64:3060-3071
23. Harada T, Chelala C, Bhakta V, Chaplin T, Caulee K, Baril P, Young BD, Lemoine NR: Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 2008, 27:1951-1960
24. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122
25. Abe T, Fukushima N, Brune K, Boehm C, Sato N, Matsubayashi H, Canto M, Petersen GM, Hruban RH, Goggins M: Genome-wide allelotypes of familial pancreatic adenocarcinomas and familial and sporadic intraductal papillary mucinous neoplasms. Clin Cancer Res 2007, 13:6019-6025
26. Howe JA, Newport JW: A developmental timer regulates degradation of cyclin E1 at the midblastula transition during Xenopus embryogenesis. Proc Natl Acad Sci USA 1996, 93:2060-2064
27. Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH, Kern SE: BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 2003, 163:1255-1260
28. Sutherland RL, Musgrove EA: Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004, 9:95-104
29. Ross JS, Greene B: Targeted therapy in oncology: the agony and ecstasy of personalized medicine. Expert Rev Anticancer Ther 2001, 1:321-322
30. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68:6084-6091
31. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N: BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362